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The clinical efficacy of a systemically administered
drug acting on the central nervous system depends
on its ability to pass the blood-brain barrier, which
is regulated by transporter molecules such asABCB1
(MDR1). Here we report that polymorphisms in the
ABCB1 gene predict the response to antidepressant
treatment in those depressed patients receiving
drugs that have been identified as substrates of
ABCB1 using abcb1ab double-knockout mice. Our
results indicate that the combined consideration of
both the medication’s capacity to act as an ABCB1-
transporter substrate and the patient’sABCB1 geno-
type are strong predictors for achieving a remission.
This finding can be viewed as a further step into
personalized antidepressant treatment.INTRODUCTION
Antidepressants are the first-line treatment for major depression,
but their overall clinical efficacy is unsatisfactory, as remission
(i.e., full resolution of depressive symptoms) occurs in only one-
third of the patients after a trial with an adequately dosed single
drug (Trivedi et al., 2006), and remission rates further decline
following successive treatment failures (Rush et al., 2006). This
situation is particularly alarming in view of the fact that major de-
pression constitutes one of the greatest disease burdens world-
wide and is anticipated to be the second leading global disease
burden by the year 2020, trailing only cardiovascular disease
(Murray and Lopez, 1996). Apart from other causes, one possible
reason for poor response to antidepressants is their inadequate
penetration into the central nervous system, which depends on
their ability to pass the blood-brain barrier (BBB). This barrier in-
cludes active transporters that are expressed at the luminal
membrane of the endothelial cell lining, the small blood capillar-
ies that form the BBB. These molecules actively transport their
substrates against a concentration gradient out of the cells back
into the blood circulation, thus potentially keeping brain drug
concentrations low. One of the best-studied transporter mole-
cules is P-glycoprotein (P-gp) (Cordon-Cardo et al., 1989; Thie-baut et al., 1987). P-gp is a member of the highly conserved
superfamily of ATP-binding cassette (ABC) transporter proteins
(Ambudkar et al., 1999). In humans, this 170 kDa glycoprotein
is encoded on chromosome 7 by the ABCB1 gene, also known
as the multidrug resistance 1 (MDR1) gene (Callen et al., 1987).
P-gp acts as an active efflux pump for a wide range of com-
pounds, including a number of drugs and steroid hormones
(Schinkel et al., 1996; Uhr et al., 2000, 2002). P-gp at the BBB
thus regulates intracerebral concentrations and, by extension,
may affect the clinical response of CNS-targeting drugs that
are substrates of this transporter.
In this report we show that by using mice in which the homo-
logs of the human ABCB1 gene are deleted it is possible to clas-
sify which antidepressants are ABCB1-transporter substrates.
The clinical usefulness of such a classification has been vali-
dated in a clinical study showing that ABCB1 gene variants pre-
dict the treatment course and outcome in those patients treated
with antidepressants that are ABCB1-transporter substrates.
RESULTS
Experiments Using abcb1a and abcb1b
Double-Knockout Mice
Since P-gp function is only critical for drugs that are substrates of
P-gp in humans, we developed an in vivo assay using mouse
mutants lacking the homologs of the human ABCB1 gene (i.e.,
abcb1ab knockout mice). After administration of antidepres-
sants for 11 days with subcutaneously implanted osmotic infu-
sion pumps, we observed that the intracerebral concentrations
of citalopram (F7,8 = 35.4; p < 0.001), venlafaxine (F7,8 = 30.7;
p < 0.001), and its active metabolite d-venlafaxine (F7,8 = 4.5;
p = 0.022) are regulated by P-gp. The brain concentrations of
citalopram, venlafaxine, and d-venlafaxine were 3.0, 1.7, and
4.1 times higher in the mutant mice compared to their wild-
type littermates (see Table S1 available online). This was not
the case for mirtazapine (F8,9 = 3.0; p = 0.58). No differences in
plasma antidepressant concentrations were found between
abcb1ab (/) mutants and their wild-type littermates for any
of the drugs and metabolites investigated (Table S1).
The blood-organ barrier function is represented in Figure 1 as
an organ/plasma concentration ratio. In the animals lacking
P-gp, the penetration of citalopram, venlafaxine, and d-venlafax-
ine into the brain is 3.7, 1.8, and 3.6 times higher than in controlNeuron 57, 203–209, January 24, 2008 ª2008 Elsevier Inc. 203
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found for citalopram, venlafaxine, and d-venlafaxine in contrast
to mirtazapine, which is in keeping with a blood-testis barrier
regulated by P-gp.
Human SNP Association Study
If a patient is treated with a substrate of P-gp, functionally rele-
vant genetic variants in the ABCB1 transporter could influence
intracerebral drug concentrations and thereby clinical response.
To test this hypothesis, we analyzed the association of single-
nucleotide polymorphisms (SNPs) in the ABCB1 gene with the
time until remission is achieved in patients under different anti-
depressants.
To that aim we investigated 95 SNPs in ABCB1, 74 of which
were polymorphic. Information on chromosome position, puta-
tive function, HWE, minor allele frequencies (MAF), and the
number of patients genotyped are presented in Table S2. The
average intermarker distance of informative SNPs was 3.5 kb
over the 262 kb long ABCB1 region on chromosome 7, including
all tagging SNPs of the HapMap project.
Because P-g does not influence cerebral penetration of all
antidepressants, patients were divided in two subgroups: one
group including patients treated with substrates of P-gp (citalo-
pram, paroxetine, amitriptyline, and venlafaxine), the other one
including patients treated with nonsubstrates (mirtazapine)
(Uhr et al., 2000, 2003, 2007; Uhr and Grauer, 2003; Grauer
and Uhr, 2004).
All polymorphic SNPs were tested for genotypic association
with the phenotype remission after 4, 5, or 6 weeks.
Table S3 shows the empiric p values of this analysis deter-
mined by applying 106 permutations and corrected for age and
sex for both the entire group and the two subgroups.
An association with p values of <0.001 was found only in
the subgroup including patients who received drugs that wereFigure 1. Blood-Organ Barrier Function for
Antidepressant Drugs
Organ/plasma ratios of drug concentration in
abcb1ab/ mice compared to wild-type controls
after subcutaneous administration of citalopram
(A), mirtazapine (B), or venlafaxine (C and D) for
11 days via osmotic pumps. The organ/plasma
ratios for citalopram (A), mirtazapine (B), venlafax-
ine (C), and desmethyl-venlafaxine (D) are shown
as percentage of the control. An asterisk indicates
a significant difference between the knockout
mutants and the control mice (univariate F tests
in MANOVA, p values < 0.05). Cerebrum (cer),
spleen (spl), kidney (kid), liver (liv), testes (tes), and
lung (lun) were investigated. Values are shown as
means ± SEM.
substrates of P-gp. The associated
SNPs were rs2235067, rs4148740,
rs10280101, rs7787082, rs2032583,
rs4148739, rs11983225, rs10248420,
rs2235040, rs12720067, and rs2235015.204 Neuron 57, 203–209, January 24, 2008 ª2008 Elsevier Inc.This association analysis for all polymorphic SNPs and pheno-
types was conducted according to Fisher’s product method
(FPM) (Fisher, 1932) as implemented in WG-Permer (http://
www.wg-permer.org) for the genotypic and allelic models. Cor-
rection for multiple testing was performed using the minimum
P method of Westfall and Young (1993). Table 1 shows the p
values of FPM over all SNPs, sorted by phenotypes and models,
as well as over all SNPs and all phenotypes, sorted bymodel and
the Westfall-Young corrected p values. In the group of patients
taking substrates of P-gp, there exist highly significant associa-
tions between the genetic variability of the SNPs tested and both
the remission of depressive symptoms in weeks 4, 5, and 6 and
the combination of these remission variables. In this group of pa-
tients, the Westfall and Young corrected p values over all SNPs
and phenotypes was 0.00040 and 0.00016 for the genotypic and
allelic analysis. In the group of patients taking drugs that are not
substrates of P-gp, there was no significant association.
Figure 2 presents the genotype distribution of the SNP
rs2032583 for patients who remitted after 4 weeks and those
who did not. In the group of patients receiving antidepressants
that are substrates of P-gp, there are clear differences in the
genotype distribution between remitters and nonremitters (Fig-
ure 2A). While in the group of nonremitters patients carrying
the C allele made up 9.5%, their percentage in the group of re-
mitted patients was 45%. The 2 3 3 table Cochran-Armitage
test yielded a c2 of 15.8, p = 0.00007, for patients receiving the
P-gp substrates and a c2 of 0.004, p = 0.945, for patients receiv-
ing a non-P-gp substrate. If C carriers are treated with drugs that
are substrates of P-gp, they have amarkedly higher approximate
relative risk for remission after 4 weeks. The odds ratio (approx-
imate relative risk) was 7.72 (95% confidence interval limits 2.80
and 21.32) with p = 0.000065 in the 2 3 2 table Fisher’s exact
test. For any particular negative test result (noncarrier), the
probability that it was true-negative (nonremission) was 81.5%.
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sion (single episode and recurrent depression, n = 98), the
odds ratio was 9.4 (95% confidence interval limits 3.0 and
29.4) with p = 0.000081.
For patients receiving non-P-gp substrates, there are no differ-
ences in the genotype distribution between remitters and nonre-
mitters (Figure 2B). The odds ratio was 1.12 (95% confidence
interval limits 0.38 and 3.37) with p = 1 in Fisher’s exact test.
For a better presentation of the time course of remission up to
week 6, a survival analysis (Cox regression) was performed. Fig-
ure 3 shows the decrease in nonremitters (i.e., patients who are
still ill) for all patients and the two subgroups during the first
6 weeks depending on their genotype. For rs2032583, a distinc-
tion was made between C carriers and noncarriers; for rs
2235015 (an associated SNP located outside the linkage dis-
equilibrium block containing rs2032583) between T carriers and
noncarriers. The group of patients treated with a substrate of
P-gp shows clear differences depending on the genotype. For
instance, after 6 weeks, 62% of the patients who are non-C car-
riers of the SNP rs2032583 had not remitted, while this was the
case in only 25% of the C carriers.
The values of the Wald statistics and p values for the other
SNPs with highly significant association in the FPM are shown
in Table S4 and confirm the association using FPM.Case-Control Association
A control group of 362 subjects was genotyped for rs2032583
and rs2235015, the representative SNPs in the haplotype blocks
3 and 5 in the LD map (Figure S1). Subjects were randomly se-
lected from a Munich-based community sample and negative
for lifetime psychiatric axis I disorders (M-CIDI) and severe so-
matic diseases. Controls did not differ from the patient sample
regarding gender distribution (p = 0.603), age (p = 0.322), or eth-
nicity (100% Caucasians in both samples). Genotype tests were
performed using Fisher’s exact test on a 2 3 3 table. We ob-
served no significant case-control association for rs2032583
and rs2235015 (Fisher’s exact test, p = 0.669 and 0.351).
DISCUSSION
To our knowledge, our results provide for the first time evidence
that genetic variants in the ABCB1 gene account for differences
in the clinical efficacy of antidepressants, most likely by influenc-
ing their access to the brain. Here we report that antidepressant-
induced remission of depressive symptoms is predicted by
SNPs in the ABCB1 gene among those depressed patients
who were treated with drugs that are substrates of the ABCB1-
encoded P-glycoprotein. To identify which antidepressants
administered to patients are substrates of the P-glycoprotein,Figure 2. Distribution of rs2032583 Geno-
types
Percentage of rs2032583 genotypes in the groups
‘‘nonremitters’’ and ‘‘remitters’’ for patients treated
with substrates of P-gp (A) (amitriptyline, citalo-
pram, paroxetine, or venlafaxine) and those
treated with non-P-gp substrates (B) (mirtaza-
pine).Table 1. Fisher’s Product and Westfall/Young Analysis
Fisher’s Product and Westfall/Young Correction over All SNPs
All Patients Substrates of P-gp Nonsubstrates of P-gp
Remission Fisher’s Product Westfall/Young Fisher’s Product Westfall/Young Fisher’s Product Westfall/Young
4 weeks genotypic 0.191 0.466 0.00034 0.00011 0.775 0.712
4 weeks allelic 0.136 0.678 0.00039 0.000048 0.565 0.829
5 weeks genotypic 0.015 0.132 0.0084 0.0042 0.014 0.056
5 weeks allelic 0.005 0.039 0.0019 0.0021 0.160 0.137
6 weeks genotypic 0.513 0.615 0.0071 0.013 0.644 0.621
6 weeks allelic 0.327 0.233 0.0012 0.00049 0.904 0.856
Fisher’s Product and Westfall/Young Correction over All SNPs and over All Phenotypes
genotypic 0.068 0.309 0.00036 0.00040 0.160 0.136
allelic 0.024 0.099 0.000094 0.00016 0.557 0.340
An analysis of all polymorphic SNPs and phenotypes was conducted according to Fisher’s product method (FPM) for the genotypic und allelic models.
For FPM, as a single statistic is formed, no further correction for multiple testing is necessary. We also give result for the minimum P of Westfall and
Young, which is a more conventional method controlling the family-wise error rate. Bold values indicate significant results.Neuron 57, 203–209, January 24, 2008 ª2008 Elsevier Inc. 205
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were studied. Whereas P-gp is encoded by a single gene in hu-
mans (ABCB1), there are two homologs in mice, the abcb1a and
abcb1b genes (Devault and Gros, 1990). Although abcb1a and
abcb1b are not always expressed in the same organs, the overall
distribution of these genes in mouse tissue coincides with that of
the single ABCB1 gene in humans, indicating that abcb1a and
abcb1b together function in the same manner in the mouse as
in human ABCB1. It has not yet been possible to predict the
affinity of a substrate to P-gp from its chemical structure, hydro-
phobicity, lipophilicity, or charge. The mouse model reported
herein allowed us to show in earlier studies that citalopram, ven-
lafaxine, paroxetine, and amitriptyline were substrates of P-gp at
the blood-brain barrier, while mirtazapine and fluoxetin were not
(Uhr et al., 2000, 2003, 2007; Uhr and Grauer, 2003; Grauer and
Uhr, 2004). This conclusion was drawn after administration of a
single dose. In this study, the drugs were administered over an
extended time period to investigate the time-dependent interac-Figure 3. Cox Regression Analysis for
rs2032583 and rs2235015
A Cox regression analysis for remission was
performed for the SNPs 2032583 (A–C) and
rs2235015 (D–F) dependent from the genetic
feature ‘‘C carrier’’ (rs2032583) or ‘‘T carrier’’
(rs2235015). The Figure shows the time course
of nonremitters (i.e., depressed patients). It de-
picts the examination of all patients (A and D)
and the two subgroups of patients receiving sub-
strates of P-gp (B and E) and those receiving
non-P-gp substrates (C and F).
tion between the drug and P-gp. We
show that two structurally different anti-
depressants (citalopram and venlafaxine)
were both substrates of P-gp at the BBB,
as the brain drug concentration in mu-
tants not carrying the genes coding for
P-gp was increased (Table S1 and Fig-
ure 1). In contrast, the penetration of mir-
tazapine into the brain is not influenced
by P-gp. The important role of P-gp was
further supported by the fact that drug
andmetabolite organ concentrations and
organ/plasma ratios of all antidepres-
sants investigated did not differ between
mutant and wild-type littermates in those
organs that either lack P-gp completely
or in which P-gp is not expressed in en-
dothelial cells, such as the spleen, kid-
ney, liver, and lung. These results show
that some but not all antidepressants
are substrates of P-gp in mice and, in ad-
dition, that this characteristic is seen after
both single dose and repeated adminis-
tration (Uhr et al., 2000, 2003; Uhr and
Grauer, 2003).206 Neuron 57, 203–209, January 24, 2008 ª2008 Elsevier Inc.To answer the question whether differences in the access of
antidepressants into the brain might influence treatment out-
come, we used the data from the Munich Antidepressant Re-
sponse Signature (MARS) study (http://www.MARS-depression.
de) in which we investigated the genetic variability of the ABCB1
gene of 443 inpatients with depressive disorder receiving anti-
depressants.
Numerous papers describe polymorphisms in ABCB1 (Hoff-
meyer et al., 2000; Kim et al., 2001; Ito et al., 2001; Cascorbi
et al., 2001; Tanabe et al., 2001; Cascorbi, 2006), and amultitude
of single-nucleotide polymorphisms (SNPs) are listed in public
SNP databases. The genetic variability of all polymorphic SNPs
studied and the recovery from depressive symptoms were ex-
amined in a summarizing model using Fisher’s product method.
After correction for multiple testing, we found a highly significant
association between the genotypes or allele frequencies of the
ABCB1 gene and remission in weeks 4, 5, and 6 only in patients
receiving substrates of P-gp (Table 1). For a better presentation
Neuron
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week 6 including all patients enrolled in the study, a Cox regres-
sion survival analysis was performed. As demonstrated in Fig-
ure 3 and Table S4, only those patients receiving substrates of
P-gp showed genotype-dependent, highly significant target
parameter differences during the clinical course, achieving a
remission with a score of <10 on the HAM-D-scale.
As exemplified in Figure 2 for the SNP rs2232583, the geno-
type distribution differs between the patient groupwith remission
versus the group without remission among patients treated with
a P-gp substrate for 4 weeks. The probability of being remitted
from depression after 4 weeks is increased for C carriers treated
with substrates of P-gp (odds ratio: 7.72, p = 0.000065). In con-
trast, it was predictable that patients carrying the TT genotype
will not be remitted after a 4 week treatment period. In the group
of patients receiving the nonsubstrate mirtazapine, there was no
difference found between the genotypes of remitters and nonre-
mitters. The group characteristics for the representative SNP
rs2032583, depending on the genotype, did not differ between
the two subgroups ‘‘patients treated with P-gp substrates’’
and ‘‘patients treated with non-P-gp substrates’’ (Table S5).
The Cox regression analysis did not reveal any significant dif-
ferences for remission rates (HAM-D < 10) in the first 6 weeks
(Wald value = 0.125; sig = 0.72) between the subgroup of pa-
tients receiving drugs that are substrates of P-pg and the sub-
group of patients receiving drugs that are not substrates of
P-gp, allowing us to reject the possibility that differences in
drug efficacy account for our different findings. In fact, the drugs
used here proved to be especially effective according to large
comparative studies required for approval. It is only the com-
bined consideration of both the patient’s ABCB1 genotype and
the medication’s P-gp substrate status that identifies a group
of patients exhibiting a clearly better remission rate than patient
populations assembled on the basis of the patient’s genotype or
the medication’s P-gp substrate status alone.
SNPs in ABCB1 have been reported to influence intestinal
uptake and thus plasma levels of drugs (Hoffmeyer et al., 2000;
Sakaeda et al., 2003). However, the various genotype-depen-
dent remission rates found in this study were not due to different
doses or plasma drug levels, which confirms that monitoring
plasma antidepressant levels is not reliable to predict adequacy
of treatment (Supplemental Data).
All highly associated SNPs are located in introns and with
the exception of rs2235015 located in a single haplotype block
(Figure S1). The SNPs rs2235067, rs4148740, rs2032583,
rs4148739, rs11983225, s2235040, and rs12720067, as well as
the SNPs rs7787082 and rs10248420, exhibit an r2 of >0.8 with
each other. This high degree of LD proscribes to single one of
them out as a potential functional variant based on the strength
of association only. We speculate that SNPs in LDs with these
or a haplotype thereof influence intronic regulatory elements
located between exons 10 and 24. In fact, resequencing all
exons and exon-intron junctions excluded the possibility that
the potential functional polymorphism could be exonic or alter
splicing (Supplemental Data). In addition, the LD block contain-
ing all associated SNPs in our studies as well as the ones known
in HapMap is separated from all predicted promoter elements
as well as the neighboring genes by recombination hotspots(Figures S1 and S2), making it unlikely that the associated
SNPs are markers for functional variants in these areas. Further-
more, the area delimited by these SNPs contains several highly
conserved intronic regions as well as two regions with a high
density of human-mouse-rat conserved transcription factor
binding sites (Figure S3). This could be related to the presence
of evolutionarily conserved functional intronic regulatory regions,
which are gaining more and more importance (The ENCODE
Project Consortium, 2007).
Recently, McMahon et al. (2006) reported that African-Ameri-
cans responded less well to an established antidepressant than
Caucasians. They attributed this difference to the higher fre-
quency of the A allele in a specific SNP in the serotonin 2 A
receptor gene. In this context, it is to be noted that the ABCB1
gene and in particular the SNPs described by us predicting the
therapeutic outcome exhibit considerable ethnic differences
(Kim, 2002; Tang et al., 2002, 2004; Kroetz et al., 2003). Thus,
the current finding indicates that variant ABCB1 genotypes con-
tribute to differences in treatment outcome across ethnic groups
and further encourages studies to elucidate the clinical implica-
tions of these differences across ethnic groups.
The general conclusion to be drawn is that any drug adminis-
tered to treat CNS diseases should be analyzed for its P-gp
substrate status, which can be determined by using abcb1ab
knockout mice. From a clinical point of view, the findings warrant
that patients receiving a drug that is a P-gp substrate for the
treatment of brain diseases are genotyped to exclude the possi-
bility that a patient receives a drug that fails to enter the CNS
to an extent required for efficacy. The combination of therapeutic
drug monitoring (TDM) involving enteral drug intake and cyto-
chrome P450 drug metabolism and P-gp genotyping for detect-
ing the drug’s bioavailability in the brainmaypredict the response
of an individual patient to a certain drug. In addition, side effects
of drugs acting on the CNS may be caused by a weakened P-gp
function. Thus, knowing the P-gp status couldmake it possible to
predict central side effects of drugs both acting on the CNS and
peripherally.
Finally, the interdependence of P-gp substrate capacity and
ABCB1 genotype needs to be considered in future drug develop-
ment, because drugs that differ in their P-gp substrate capacity
need to be evaluated in clinical trials where study populations
are stratified according to the ABCB1 genotype.
EXPERIMENTAL PROCEDURES
Experiments Using Transgenic Animals
Materials and Animals
Materials and animals were already described (Uhr et al., 2003; Uhr and Gra-
uer, 2003) and are represented in the Supplemental Data section. All animal
experiments were conducted in accordance with the Guide for the Care and
Use of Laboratory Animals of the Government of Bavaria, Germany. Age,
weight, and group size of the mice used are shown in Table S8.
Experimental, Extraction Procedures, HPLC, and Statistics
Citalopram, mirtazapine, and venlafaxine dissolved in 0.9% sodium chloride
and 0.5% ethanol were administered subcutaneously in the nape of the neck
through surgically implanted osmotic infusion pumps (Alzet micro-osmotic
pump, Alza Corporation, Palo Alto, CA, USA), which continuously delivered the
drugs at the scheduled concentrations (citalopram and mirtazapine 60 mg/d;
venlafaxine 300 mg/d). After 11 days, the mice were anesthetized and sacri-
ficed. The dissected organs were homogenized, a liquid-liquid extractionNeuron 57, 203–209, January 24, 2008 ª2008 Elsevier Inc. 207
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(HPLC) measurements and statistics were carried out as described elsewhere
(Uhr et al., 2003, and Supplemental Data).
Human Genetic Studies
Description of Patients
The study included 443 inpatients with depression who were treated at the
Max Planck Institute of Psychiatry (MPI), Munich/Germany.
Patients were included in this study within 1–3 days of admission and diag-
nosed by trained psychiatrists according to the Diagnostic and Statistical
Manual of Mental Disorders (DSM) IV criteria. Patients with depressive dis-
order due to a medical or neurological condition were excluded. Ethnicity
was recorded using a self-report sheet for nationality, native language, and
ethnicity of the subject and of all four grandparents. The study was approved
by the local ethics committee and written informed consent obtained from all
subjects.
The study was designed as a pharmacogenetic study (Munich Antidepres-
sant Response Signature [MARS] project) (Binder et al., 2004) to discover
biomarkers and genotypes predictive of clinical outcome in relationship to
treatment, which was at doctor’s choice. The antidepressant plasma concen-
trations were monitored to ascertain clinically efficient drug levels.
Patients were subdivided into two groups according to the antidepressant
property as P-gp substrate. Patients taking antidepressants that are sub-
strates of P-gp received amitriptyline, paroxetine, venlafaxine, or citalopram,
and patients taking antidepressants that are not substrates of P-gp received
mirtazapine for at least 4 weeks within the first 5 weeks of treatment. In addi-
tion, theywere not allowed to take other antidepressants formore than 3weeks
(with the exception of trimipramine, which was allowed in a daily dose of up to
100 mg to facilitate sleep). If a patient was discharged prior to week 5, she/he
had to take the respective drugs for 3weekswhen hospitalized for 4weeks and
for 2 weeks in the case of a 3 week hospitalization. The group characteristics
number of patients (% women), age, Hamilton Depression Rating Scale
(HAM-D) at inclusion, age at onset, illness duration in years, number of previous
episodes, number of former hospitalizations, duration of actual episode,
ethnicity, comedication, and diagnosis are shown in Tables S5 and S6 for the
representative SNPs rs2032583 and rs2235015 depending on the genotype.
Not all patients finished the weekly psychopathology ratings. After weeks 4,
5, and 6, the data of only 366 (83%), 324 (73%), and 297 (67%) patients were
available for evaluation. This attrition was due to the patients’ rapid recovery,
discharge against doctor’s advice, or refusal of further participation. After
discharge from the hospital, no further weekly psychopathology ratings were
collected.
Psychopathology and Definition of Response to Antidepressant
Drug Treatment
Trained raters using the 21 itemHAM-D scale assessed the severity of psycho-
pathology at admission. Patients fulfilling the criteria for at least one moderate
depressive episode (HAM-D R 14) entered the analysis. Ratings were per-
formed within 3 days of admission and then weekly until discharge.
Remission was defined as reaching a total HAM-D score of less than 10.
The time period was chosen because it is considered to be necessary for an
antidepressant drug to display its clinical efficacy.
DNA Preparation, SNP Selection, and Genotyping
Forty milliliters of EDTA blood was drawn from each patient, and DNA was ex-
tracted using the Puregene whole-blood DNA extraction kit (Gentra Systems,
Minneapolis, MN, USA).
Ninety-five ABCB1 (NM_000927) SNPs were genotyped. SNPs were se-
lected from dbSNP (http://www.ncbi.nlm.nih.gov:80/) or part of the Illumina
Sentrix Human-1 100 k BeadChips.
Genotyping was performed on a matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometer (MassArray system) employing
the Spectrodesigner software (Sequenom; San Diego, CA, USA) for primer se-
lection and multiplexing and the homogeneous mass extension (hMe) process
for producing primer extension products. Cleaned extension products were
analyzed by means of a mass spectrometer (Bruker Daltronik) and the peaks
identified using the SpectroTYPER software (Sequenom). Only if the call rate
of a plate was higher than 90% were the genotypes used for evaluation.208 Neuron 57, 203–209, January 24, 2008 ª2008 Elsevier Inc.SNPs that could not be examined by means of the Sequenom technology
were tested by pyrosequencing (Biotage, Uppsala, Sweden).
rs7779562, rs4148738, rs2235033, rs10264856, rs10267099, rs7796247,
and rs10275625 were performed on Sentrix Human-1 Genotyping BeadChips
(Illumina Inc., San Diego, CA, USA) according to the manufacturer’s standard
protocols. The SNPs rs2235048, rs1045642, rs2032583, rs2235046,
rs1202169, rs2235015, and rs1202172 were performed using both the Seque-
nom and Illumina technology. The results were congruent in more than 99%.
The tetra-allelic SNP rs2032582 was measured with the light-cycler using
allele-specific hybridization probes.
Statistics
Exact tests to detect deviations from Hardy Weinberg equilibrium (HWE)
(Wigginton et al., 2005) were performed for all SNPs (Table S2).
To calculate whether there exists a significant association between pheno-
type variables and genetic variability in the ABCB1 gene, the multivariate
Fisher’s product method (FPM) was employed. Phenotype variables were cor-
rected for the effects of age and gender by calculating linear regression resid-
uals using the statistic package software SPSS Release 14.0.0 (Chicago, IL,
USA). Bivariate associations between SNP genotyping data and phenotypes
were tested in an ANOVA analysis. Empiric p values were calculated by apply-
ing 106 permutations (phenotypes randomly redistributed over the genotypes).
Fisher’s product method (FPM) (Fisher, 1932) includes the residuals of the
phenotype variables remission after 4 weeks, remission after 5 weeks, remis-
sion after 6 weeks, and the genotype variables from all polymorphic SNPs.
P value correction for multiple comparisons was done by resampling (106
permutations).
To correct for multiple testing, the permutation method by Westfall and
Young (1993) was applied to take advantage of the dependence structure be-
tween the SNPs and the phenotypes. We performed the entire analysis scan
106 times using phenotypes randomly redistributed over the genotypes.
Finally, a Cox regression survival analysis was carried out with the statistic
package software SPSS Release 14.0.0 (Chicago, IL, USA), examining remis-
sion incidence (HAM-D < 10) during the first 6 weeks of treatment, with age and
gender as covariates.
Supplemental Data
The Supplemental Data for this article can be found online at http://www.
neuron.org/cgi/content/full/57/2/203/DC1/.
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